AzacitidineAntimetabolites, AntineoplasticMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicTreatment OutcomeAncylostomatoideaChromatography, Supercritical FluidAntiplatyhelmintic AgentsTrichurisPapio hamadryasAnthelminticsCompassionate Use TrialsAntimalarialsInjections, SubcutaneousLeukemia, Myeloid, AcutePharmacogeneticsAnemia, RefractoryConsolidation ChemotherapyDrug ResistanceInduction ChemotherapyAscaris lumbricoidesAnemia, Refractory, with Excess of BlastsDrug Evaluation, PreclinicalDrug ApprovalChloroquineDrug CombinationsSulfadoxineParasitologyParasitic Sensitivity TestsDNA MethylationPyrimethamineDrug MonitoringTrichuriasisParasite Egg CountDrug Administration ScheduleDNA Modification MethylasesAntineoplastic AgentsMalaria, FalciparumHelminthsPraziquantelSurvivalRecurrenceInternational AgenciesEpigenomicsHelminthiasisUnited States Food and Drug AdministrationCell Line, TumorThalidomideClinical Trials as TopicPlasmodium falciparumBiomarkers, PharmacologicalPharmaceutical PreparationsArtemisininsDisease Models, AnimalTrypanocidal AgentsFluorenesDrug Therapy, CombinationDrug Delivery SystemsRemission InductionAntineoplastic Combined Chemotherapy ProtocolsParasitemiaBiological AvailabilityAntimetabolitesAmodiaquineUgandaMalariaBlood TransfusionCytarabineDNA, ProtozoanDrug DiscoveryTetrazolium SaltsDrug DesignLeukemia, MyeloidTime FactorsDrug-Related Side Effects and Adverse ReactionsAntiprotozoal AgentsDrug TherapyDouble-Blind MethodAnti-Arrhythmia AgentsDrug Screening Assays, AntitumorMaximum Tolerated DoseAdministration, OralModels, BiologicalDose-Response Relationship, DrugRetrospective StudiesXenograft Model Antitumor AssaysRandomized Controlled Trials as TopicTreatment FailureNeoplasmsFecesAcute DiseaseGenotypeProtozoan ProteinsSensitivity and SpecificityFatigueApoptosisSurvival AnalysisDrug Resistance, NeoplasmInfusions, IntravenousReproducibility of Results